“Lapatinib L ) a dual, inhibitor of EGFR and HER2/neu tyrosine kinase activity improves overall survival (OS) in patients with metastatic BC when added to paclitaxel (SABCS 2010:P3-1424).The relative efficacy of L + taxane compared to trastuzumab (T) + taxane in the metastatic setting is unknown.”